PATENT CLAIM ANALYSIS

Application Number: 16033071
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2018-11
Patent Classification: ["514", "252160"]

Abstract:
The present disclosure is concerned with certain pyrrolopyrimidine compounds that are capable of inhibiting certain protein kinases, and especially the leucine-rich repeat kinase 2 (LRRK2) protein. Compounds of the present disclosure can be used to treat a number of disorders caused by or associated with abnormal LRRK2 kinase activity. Compounds of the present disclosure can be used to treat disorders including neurodegenerative diseases such as Parkinson's disease; precancerous conditions and cancer; autoimmune disorders such as Crohn's disease, rheumatoid arthritis and psoriasis; and leprosy (Hansen's disease). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Claim (Index 16):
The method of  claim 15 , wherein the disorder is a neurodegenerative disorder, a cancer, an autoimmune disorder, or leprosy.

Metadata:
- Claim Count in Document: 41.0
- Percentile: 95.0
- Lexical Diversity: 1.68421
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15519109', '15039763', '13922230', '14913266', '13420333']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.832141913617887
- 35 USC 102 Novelty (BERT): 0.5561689223431053
- Combined Prediction Score: 0.8045446144904089
- Mean Citation Score: 395.80136
- Max Citation Score: 458.08496
- Similarity Product: 303.3745929235268

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 0

Dataset: test